Stem definition | Drug id | CAS RN |
---|---|---|
2483 | 18883-66-4 |
None
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 407.20 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 21 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
May 7, 1982 | FDA | TEVA PHARMS USA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephropathy toxic | 95.06 | 52.94 | 17 | 148 | 9462 | 63479395 |
Chronic kidney disease | 63.47 | 52.94 | 16 | 149 | 45382 | 63443475 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephropathy toxic | 70.98 | 49.04 | 17 | 369 | 20402 | 79723600 |
Chronic kidney disease | 59.36 | 49.04 | 19 | 367 | 66135 | 79677867 |
Left ventricular dysfunction | 51.43 | 49.04 | 13 | 373 | 19348 | 79724654 |
None
Source | Code | Description |
---|---|---|
ATC | L01AD04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrosoureas |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000903 | Antibiotics, Antineoplastic |
MeSH PA | D000970 | Antineoplastic Agents |
CHEBI has role | CHEBI:25212 | metabolites |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:59517 | DNA synthesis inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pancreatic Neuroendocrine Tumor | indication | 717919005 | |
Carcinoid syndrome | off-label use | 35868009 | |
Mycosis | contraindication | 3218000 | DOID:1564 |
Viral disease | contraindication | 34014006 | DOID:934 |
Dehydration | contraindication | 34095006 | |
Infectious disease | contraindication | 40733004 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Bacterial infectious disease | contraindication | 87628006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Protozoal Infection | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.1 | acidic |
pKa2 | 12.56 | acidic |
pKa3 | 13.33 | acidic |
pKa4 | 13.57 | acidic |
None
None
None
ID | Source |
---|---|
4018094 | VUID |
N0000146432 | NUI |
D05932 | KEGG_DRUG |
4018094 | VANDF |
C0038432 | UMLSCUI |
CHEBI:9288 | CHEBI |
STZ | PDB_CHEM_ID |
CHEMBL1651906 | ChEMBL_ID |
DB00428 | DRUGBANK_ID |
D013311 | MESH_DESCRIPTOR_UI |
29327 | PUBCHEM_CID |
3824 | INN_ID |
5W494URQ81 | UNII |
10114 | RXNORM |
1423 | MMSL |
5515 | MMSL |
d00375 | MMSL |
002663 | NDDF |
16915004 | SNOMEDCT_US |
404876000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Zanosar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4636 | POWDER, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA | 18 sections |
Zanosar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4636 | POWDER, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA | 18 sections |
Zanosar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4636 | POWDER, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA | 18 sections |
Zanosar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68118-100 | POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | Unapproved drug for use in drug shortage | 3 sections |